{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T01:06:27Z","timestamp":1778288787345,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T00:00:00Z","timestamp":1589414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T00:00:00Z","timestamp":1589414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003785","name":"FundRef Registry","doi-asserted-by":"publisher","award":["B2019251"],"award-info":[{"award-number":["B2019251"]}],"id":[{"id":"10.13039\/501100003785","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s10741-020-09956-6","type":"journal-article","created":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T00:02:25Z","timestamp":1589414545000},"page":"1119-1130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cost-effectiveness analyses of sacubitril-valsartan for heart failure"],"prefix":"10.1007","volume":"26","author":[{"given":"Xiao-qi","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-shan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-qing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-juan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-yan","family":"Lao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,14]]},"reference":[{"key":"9956_CR1","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.2147\/DDDT.S148949","volume":"12","author":"JD Jackson","year":"2018","unstructured":"Jackson JD, Cotton SE, Bruce Wirta S, Proenca CC, Zhang M, Lahoz R, Calado FJ (2018) Burden of heart failure on patients from China: results from a cross-sectional survey. Drug Des Devel Ther 12:1659\u20131668","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"9956_CR2","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jama.289.2.194","volume":"289","author":"MM Redfield","year":"2003","unstructured":"Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR, Rodeheffer RJ (2003) Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289(2):194\u2013202","journal-title":"JAMA"},{"issue":"12","key":"9956_CR3","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jacc.2013.11.053","volume":"63","author":"AP Ambrosy","year":"2014","unstructured":"Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CSP, Sato N, Shah AN, Gheorghiade M (2014) The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 63(12):1123\u20131133","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"9956_CR4","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonz\u00e1lez-Juanatey JR, Harjola VP, Jankowska EA, Jessu M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail 18(8):891\u2013975","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"9956_CR5","first-page":"3","volume":"31","author":"G Dongfeng","year":"2003","unstructured":"Dongfeng G, Guangyong H, Jiang H, Wu X, Duan X, MacMahon S, Whelton PK (2003) Investigation of prevalence and distributing feature of chronic heart failure in Chinese adult population. Chin J Cardiol 31(1):3\u20136 (in Chinese)","journal-title":"Chin J Cardiol"},{"issue":"1","key":"9956_CR6","first-page":"3","volume":"23","author":"L Ma","year":"2018","unstructured":"Ma L, Wu Y, Wang W, Chen W (2018) Interpretation of the report on cardiovascular diseases in China (2017). Chin J Cardiovasc Med 23(1):3\u20136 (in Chinese)","journal-title":"Chin J Cardiovasc Med"},{"issue":"3","key":"9956_CR7","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ijcard.2013.12.028","volume":"171","author":"C Cook","year":"2014","unstructured":"Cook C, Cole G, Asaria P, Jabbour R, Francis DP (2014) The annual global economic burden of heart failure. Int J Cardiol 171(3):368\u2013376","journal-title":"Int J Cardiol"},{"issue":"6","key":"9956_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2165\/00019053-200826060-00001","volume":"26","author":"L Liao","year":"2008","unstructured":"Liao L, Allen LA, Whellan DJ (2008) Economic burden of heart failure in the elderly. PharmacoEconomics 26(6):447\u2013462","journal-title":"PharmacoEconomics"},{"issue":"13","key":"9956_CR9","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","volume":"68","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C (2017) 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 68(13):1476\u20131488","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"9956_CR10","first-page":"760","volume":"6","author":"Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology of Chinese Heart Failure Association of Chinese Medical Doctor Association","year":"2018","unstructured":"Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology of Chinese Heart Failure Association of Chinese Medical Doctor Association (2018) Chinese guidelines for the diagnosis and treatment of heart failure. Chin J Cardiol 6(10):760\u2013789 (in Chinese)","journal-title":"Chin J Cardiol"},{"issue":"14","key":"9956_CR11","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"JJ McMurray","year":"2012","unstructured":"McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, B\u00f6hm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, K\u00f8ber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, R\u00f8nnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A (2012) ESC (2012) guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur Heart J 33(14):1787\u20131847","journal-title":"Eur Heart J"},{"issue":"1","key":"9956_CR12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1524-4733.2008.00425.x","volume":"12","author":"A G\u00f6hler","year":"2009","unstructured":"G\u00f6hler A, Geisler BP, Manne JM, Kosiborod M, Zhang Z, Weintraub WS, Spertus JA, Gazelle GS, Siebert U, Cohen DJ (2009) Utility estimates for decision-analytic modeling in chronic heart failure-health states based on New York heart association classes and number of rehospitalizations. Value Health 12(1):185\u2013187","journal-title":"Value Health"},{"issue":"5","key":"9956_CR13","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.ahj.2003.09.020","volume":"147","author":"H Ardehali","year":"2014","unstructured":"Ardehali H, Qasim A, Cappola T, Howard D, Hruban R, Hare JM, Baughman KL, Kasper EK (2014) Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am Heart J 147(5):919\u2013923","journal-title":"Am Heart J"},{"issue":"3","key":"9956_CR14","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1161\/01.CIR.96.3.793","volume":"96","author":"PR Pagley","year":"1997","unstructured":"Pagley PR, Beller GA, Watson DD, Gimple LW, Ragosta M (1997) Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability. Circulation 96(3):793\u2013800","journal-title":"Circulation"},{"issue":"9","key":"9956_CR15","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","volume":"15","author":"JJ McMurray","year":"2013","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR (2013) Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 15(9):1062\u20131073","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"9956_CR16","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993\u20131004","journal-title":"N Engl J Med"},{"issue":"10","key":"9956_CR17","doi-asserted-by":"publisher","first-page":"735","DOI":"10.7326\/M16-1932","volume":"165","author":"M Packer","year":"2016","unstructured":"Packer M, Armstrong WM, Rothstein JM, Emmett M (2016) Sacubitril-valsartan in heart failure: why are more physicians not prescribing it? Ann Intern Med 165(10):735\u2013736","journal-title":"Ann Intern Med"},{"issue":"2","key":"9956_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1017\/S0266462313000160","volume":"29","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E (2013) Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Int J Technol Assess Health Care 29(2):117\u2013122","journal-title":"Int J Technol Assess Health Care"},{"key":"9956_CR19","doi-asserted-by":"publisher","unstructured":"OECD (2020) Inflation (CPI). OCED.org. https:\/\/doi.org\/10.1787\/eee82e6e-en. Accessed on 12 March 2020","DOI":"10.1787\/eee82e6e-en"},{"key":"9956_CR20","unstructured":"World Bank, International Comparison Program database (2020) PPP conversion factor, GDP. World Bank Open Data. https:\/\/data.worldbank.org\/indicator\/PA.NUS.PPP. Accessed on 12 March 2020"},{"issue":"10","key":"9956_CR21","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40273-018-0688-4","volume":"36","author":"G Afschin","year":"2018","unstructured":"Afschin G, Ostwald DA (2018) Sacubitril\/valsartan (LCZ696): a novel treatment for heart failure and its estimated cost effectiveness, budget impact, and disease burden reduction in Germany. PharmacoEconomics 36(10):1285\u20131296","journal-title":"PharmacoEconomics"},{"issue":"10","key":"9956_CR22","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.jval.2017.05.013","volume":"20","author":"IC Ramos","year":"2017","unstructured":"Ramos IC, Versteegh MM, de Boer RA, Koenders JMA, Linssen GCM, Meeder JG, Rutten-van M\u00f6lken MPMH (2017) Cost effectiveness of the angiotensin receptor neprilysin inhibitor sacubitril\/valsartan for patients with chronic heart failure and reduced ejection fraction in the Netherlands: a country adaptation analysis under the former and current Dutch pharmacoeconomic guidelines. Value Health 20(10):1260\u20131269","journal-title":"Value Health"},{"key":"9956_CR23","first-page":"w14533","volume":"147","author":"Z Ademi","year":"2017","unstructured":"Ademi Z, Pfeil AM, Hancock E, Trueman D, Haroun RH, Deschaseaux C, Schwenkglenks M (2017) Cost-effectiveness of sacubitril\/valsartan in chronic heart-failure patients with reduced ejection fraction. Swiss Med Wkly 147:w14533","journal-title":"Swiss Med Wkly"},{"issue":"10","key":"9956_CR24","doi-asserted-by":"publisher","first-page":"681","DOI":"10.7326\/M16-0057","volume":"165","author":"AT Sandhu","year":"2016","unstructured":"Sandhu AT, Ollendorf DA, Chapman RH, Pearson SD, Heidenreich PA (2016) Cost-effectiveness of sacubitril\u2013valsartan in patients with heart failure with reduced ejection fraction. Ann Intern Med 165(10):681\u2013689","journal-title":"Ann Intern Med"},{"issue":"6","key":"9956_CR25","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamacardio.2016.1747","volume":"1","author":"TA Gaziano","year":"2016","unstructured":"Gaziano TA, Fonarow GC, Claggett B, Chan WW, Deschaseaux-Voinet C, Turner SJ, Rouleau JL, Zile MR, McMurray JJ, Solomon SD (2016) Cost-effectiveness analysis of sacubitril\/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. JAMA Cardiol 1(6):666\u2013672","journal-title":"JAMA Cardiol"},{"issue":"2","key":"9956_CR26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/13696998.2017.1387119","volume":"21","author":"L Liang","year":"2018","unstructured":"Liang L, Bin-Chia Wu D, Aziz MIA, Wong R, Sim D, Leong KTG, Wei YQ, Tan D, Ng K (2018) Cost-effectiveness of sacubitril\/valsartan versus enalapril in patients with heart failure and reduced ejection fraction. J Med Econ 21(2):174\u2013181","journal-title":"J Med Econ"},{"issue":"5","key":"9956_CR27","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jchf.2016.02.007","volume":"4","author":"JB King","year":"2016","unstructured":"King JB, Shah RU, Bress AP, Nelson RE, Bellows BK (2016) Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction. JACC Heart Fail 4(5):392\u2013402","journal-title":"JACC Heart Fail"},{"issue":"5","key":"9956_CR28","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/phar.2108","volume":"38","author":"PM Zueger","year":"2018","unstructured":"Zueger PM, Kumar VM, Harrington RL, Rigoni GC, Atwood A, DiDomenico RJ, Touchette DR (2018) Cost-effectiveness analysis of sacubitril-valsartan for the treatment of heart failure with reduced ejection fraction in the United States. Pharmacotherapy 38(5):520\u2013530","journal-title":"Pharmacotherapy"},{"issue":"3","key":"9956_CR29","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jval.2016.10.015","volume":"20","author":"S Van der Pol","year":"2017","unstructured":"Van der Pol S, Degener F, Postma MJ, Vemer P (2017) An economic evaluation of sacubitril\/valsartan for heart failure patients in the Netherlands. Value Health 20(3):388\u2013396","journal-title":"Value Health"},{"issue":"12","key":"9956_CR30","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/heartjnl-2016-310661","volume":"104","author":"J Mcmurray","year":"2018","unstructured":"Mcmurray J, Trueman D, Hancock E, Cowie MR, Briggs A, Taylor M, Mumby-Croft J, Woodcock F, Lacey M, Haroun R, Deschaseaux C (2018) Cost-effectiveness of sacubitril\/valsartan in the treatment of heart failure with reduced ejection fraction. Heart 104(12):1006\u20131013","journal-title":"Heart"},{"issue":"5","key":"9956_CR31","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40256-018-0288-x","volume":"18","author":"R Krittayaphong","year":"2018","unstructured":"Krittayaphong R, Permsuwan U (2018) Cost-effectiveness analysis of sacubitril-valsartan compared with enalapril in patients with heart failure with reduced ejection fraction in Thailand. Am J Cardiovasc Drugs 18(5):405\u2013413","journal-title":"Am J Cardiovasc Drugs"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-020-09956-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-020-09956-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-020-09956-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T06:29:19Z","timestamp":1627108159000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-020-09956-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,14]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["9956"],"URL":"https:\/\/doi.org\/10.1007\/s10741-020-09956-6","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,14]]},"assertion":[{"value":"14 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}